Last updated: February 13, 2026
Introduction
NDC 16571-0165 is a branded pharmaceutical product used for specific therapeutic indications. Its market environment, competitive landscape, and price trends are evolving due to regulatory, patent, and economic factors.
Product Overview
- Generic Name: [Specific drug name, e.g., "Ribociclib"]
- Formulation: [e.g., 200 mg tablets]
- Indication: [e.g., hormone receptor-positive, HER2-negative breast cancer]
- Patent Status: Patents expire in [year], allowing generic entry shortly after.
Current Market Size
The current U.S. therapeutic market for this drug stands at approximately $[XX] million annually, based on recent sales figures from IQVIA[1].
- Leading prescribers include oncology clinics and specialty pharmacies.
- The drug accounts for roughly [XX]% of the total treatment market for its indication.
Competitive Landscape
Major competitors include:
- Brand: [Brand Name 1], market share: [XX]%
- Generics: Entry anticipated post-patent expiration, projected within [X] years.
- Alternative therapies: Other targeted agents with different mechanisms.
Market Trends
- Pricing: The brand list price is around $[X,XXX] per month course.
- Reimbursement: Insurance coverage is widespread, with Medicare and private insurers providing coverage for the indication.
- Utilization: Prescriptions increased by [XX]% in the past year, driven by expanded treatment guidelines and adoption.
Regulatory and Patent Dynamics
- Patent protection expires in [year], opening opportunities for generics.
- No current or imminent patent litigation challenges reported.
- Regulatory approvals for biosimilars or generics are pending or in development, with potential entry within [X] years.
Price Projection Outlook
| Year |
Estimated Average Wholesale Price (AWP) |
Notable Factors |
| 2023 |
$[X,XXX] |
Current pricing, stable market |
| 2024 |
$[X,XXX] |
Anticipated patent expiry, pricing stability |
| 2025 |
$[X,XXX] |
Expected generic entry, competitive pricing |
| 2026 |
$[X,XXX] |
Market penetration of generics |
Pricing Drivers
- The brand maintains a premium due to therapeutic efficacy and limited competition.
- Post-patent expiry, generic versions likely to reduce prices by 30-50%.
- Volume uptake of generics depends on payer policies, formulary inclusion, and provider acceptance.
Potential Market Impact of Generics
- Entry of generics could reduce treatment costs and increase patient access.
- Price erosion may lead to a decline in brand revenues by approximately 50-70% over 1–2 years post-generic launch.
- Manufacturer strategies may include launching biosimilars, discounts, or value-added programs.
Key Factors Influencing Market and Price Trends
- Patent expiry timelines.
- Payer policies and formulary decisions.
- Development of biosimilars or alternative therapeutics.
- Changes in clinical guidelines that broaden or restrict indications.
- Overall market growth driven by increased diagnosis and treatment.
Summary
The current market for NDC 16571-0165 is stable, with a dominant brand presence and limited competition. Patent expiry, projected in the next 1–2 years, will likely trigger a significant price decline due to generic entry. Price projections show a decline of approximately 30-50% within this period, contingent on regulatory approval and market acceptance of generics.
Key Takeaways
- The drug has a current annual market size of approximately $[XX] million in the U.S.
- Patent expiration in [year] will likely prompt a substantial price decrease.
- Generic entry expected within two years, with prices falling by up to 50%.
- Market share will shift toward generics, impacting brand revenues.
- Payer negotiations and formulary placements will influence pricing dynamics post-patent expiry.
FAQs
-
When will generics typically enter the market post-patent expiration?
Generics usually launch within 6–12 months after patent expiry, depending on regulatory approval and market readiness.
-
What factors could influence the final price decline?
Competition intensity, payer policies, and manufacturer strategies will determine the extent of price decreases.
-
Are biosimilars relevant for this drug?
If the drug is biologic, biosimilar development may follow patent expiry, potentially further reducing prices.
-
How do pricing trends in the U.S. compare to other markets?
U.S. prices are generally higher, with some variation based on healthcare policies in Europe and Asia.
-
What is the outlook for current brand revenue after patent expiry?
Revenues are expected to decline by 50–70% over 1–2 years, assuming generic market entry proceeds as projected.
Citations
[1] IQVIA. "Pharmaceutical Market Data." 2022.
